Bone R, Lu T, Illig C R, Soll R M, Spurlino J C
3-Dimensional Pharmaceuticals Inc., Eagleview Corporate Center, 665 Stockton Drive, Suite 104, Exton, Pennsylvania 19341, USA.
J Med Chem. 1998 Jun 4;41(12):2068-75. doi: 10.1021/jm970796l.
The structure of the noncovalent complex of human alpha-thrombin with a nonpeptide inhibitor containing a central phenyl scaffold, N-[2-[5-methyl-3-(2-chlorophenylsulfonyloxy)phenoxy]ethyl]-N- methyl-4 -aminopyridine (1), has been determined to 2.20 A resolution. In addition, the thrombin-bound structures of two distinct amino acid-based inhibitors (3 and 4) containing different aminopyridine-derived guanidine mimetics have been determined. Each compound occupies the same region of the active site and projects an aminopyridine, a central hydrophobic group, and an aryl group, into the S1, S2, and aryl subsites on thrombin. Nonpeptide 1 forms only one direct intermolecular hydrogen bond to the thrombin active site and forms no hydrogen bonds to ordered molecules of solvent. Close contacts are observed between main-chain carbonyl groups on thrombin and the edges of the central phenyl and aminopyridine rings and the sulfonyl group of 1 such that atoms carrying opposite partial charges are juxtaposed. Aminopyridine groups in 3 and 4 also form close contacts with the edges of carbonyl groups on thrombin and are flexibly accommodated in the S1 subsite. Superposition of the bound conformations of 1 and D-Phe-Pro-amidobutylguanidine (2) revealed that the central phenyl scaffold of 1 substitutes for the peptide main chain of 2.
已确定人α-凝血酶与一种含中心苯基支架的非肽抑制剂N-[2-[5-甲基-3-(2-氯苯基磺酰氧基)苯氧基]乙基]-N-甲基-4-氨基吡啶(1)形成的非共价复合物的结构,分辨率达到2.20 Å。此外,还确定了两种不同的含氨基酸抑制剂(3和4)与凝血酶结合的结构,这两种抑制剂含有不同的氨基吡啶衍生的胍模拟物。每种化合物都占据活性位点的同一区域,并将一个氨基吡啶、一个中心疏水基团和一个芳基分别伸入凝血酶的S1、S2和芳基亚位点。非肽1仅与凝血酶活性位点形成一个直接的分子间氢键,且不与有序的溶剂分子形成氢键。观察到凝血酶主链羰基与中心苯基和氨基吡啶环的边缘以及1的磺酰基之间存在紧密接触,使得带有相反部分电荷的原子并列。3和4中的氨基吡啶基团也与凝血酶羰基的边缘形成紧密接触,并灵活地容纳在S1亚位点。1和D-苯丙氨酸-脯氨酸-氨基丁基胍(2)结合构象的叠加显示,1的中心苯基支架替代了2的肽主链。